BioAdaptives, Inc. Files 8-K
Ticker: BDPT · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1575142
| Field | Detail |
|---|---|
| Company | Bioadaptives, INC. (BDPT) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
BioAdaptives filed an 8-K on Dec 5th for a Dec 3rd event, including financials.
AI Summary
BioAdaptives, Inc. filed an 8-K on December 5, 2024, reporting an event on December 3, 2024. The filing is a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, formerly known as APEX 8 Inc., is incorporated in Delaware and based in Las Vegas, Nevada.
Why It Matters
This 8-K filing indicates that BioAdaptives, Inc. has made a regulatory disclosure and submitted financial statements and exhibits, which could contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for disclosures and exhibits, not indicating immediate operational or financial distress.
Key Players & Entities
- BIOADAPTIVES, INC. (company) — Registrant
- APEX 8 Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Las Vegas, Nevada (location) — Principal executive office location
- December 3, 2024 (date) — Date of earliest event reported
- December 5, 2024 (date) — Filing date
FAQ
What specific event triggered this 8-K filing on December 3, 2024?
The filing does not specify the exact event that occurred on December 3, 2024, but it is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
What was the previous name of BioAdaptives, Inc.?
The previous name of BioAdaptives, Inc. was APEX 8 Inc., with a name change date of April 24, 2013.
Where is BioAdaptives, Inc. headquartered?
BioAdaptives, Inc. is headquartered at 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128.
What is the SIC code for BioAdaptives, Inc.?
The Standard Industrial Classification (SIC) code for BioAdaptives, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
This 8-K report was filed on December 5, 2024.
Filing Stats: 415 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-05 06:01:00
Filing Documents
- bdpt_8k.htm (8-K) — 20KB
- bdpt_ex991.htm (EX-99.1) — 5KB
- bdpt_8kimg5.jpg (GRAPHIC) — 5KB
- 0001640334-24-001825.txt ( ) — 152KB
- bdpt-20241203.xsd (EX-101.SCH) — 6KB
- bdpt-20241203_lab.xml (EX-101.LAB) — 13KB
- bdpt-20241203_cal.xml (EX-101.CAL) — 1KB
- bdpt-20241203_pre.xml (EX-101.PRE) — 8KB
- bdpt-20241203_def.xml (EX-101.DEF) — 2KB
- bdpt_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The Company issued press release on December 3, 2024, announcing the Board of Directors approval of a dividend to all common stock shareholders. The dividend is one for one with the record date projected to be in the second week of January 2025 with a payment date to be 15 days after the record date. Copies of these press releases are furnished as Exhibits 99.1 to this Current Report on Form 8-K. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release (12/2/24) 2 SIGNATURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioAdaptives, Inc. December 5, 2024 /s/ James E Keener James E Keener CEO 3